Navigation Links
Most Leukemia Patients Recover From 'Chemo Brain' After Transplant: Study
Date:5/6/2011

FRIDAY, May 6 (HealthDay News) -- A decline in memory and fine-motor skills is common among patients who undergo a bone marrow or stem cell transplant to treat leukemia or lymphoma, but most patients return to normal within five years, according to a new study.

Previous research has shown that the chemotherapy drugs these patients take before transplantation and medicines they take to prevent rejection of the transplanted cells can affect memory and motor skills. This study looked at how long it takes them to recover from those problems, often referred to as "chemo brain."

The study included 92 patients with chronic myeloid leukemia, acute leukemia, lymphoma or myelodysplastic syndrome, in which the bone marrow does not function normally. The patients had received an allogeneic (cells donated by another person) bone marrow or stem cell transplant.

After treatment, the patients' memory and motor skills were assessed. Most patients showed substantial improvement in neurocognitive function between one and five years after their transplant.

But deficits, described as mostly mild, persisted for five years in nearly 42 percent of the patients, a finding that surprised the researchers at the Fred Hutchinson Cancer Research Center in Seattle.

"We really thought the rates would be lower," study leader Karen Syrjala, director of Biobehavioral Sciences, said in a Hutchinson news release. "We were thrilled to see that people recovered substantially, but we also were surprised that so many people did continue to have measurable deficits in some areas even after five years."

Further research is needed to identify the reasons for these persistent deficits, she added.

The study was published May 2 online in the Journal of Clinical Oncology.

More information

The U.S. National Heart, Lung, and Blood Institute has more about bone marrow and stem cell transplant.

-- Robert Preidt

SOURCE: Fred Hutchinson Cancer Research Center, news release, May 3, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Agent selectively targets malignant B cells in chronic leukemia, study shows
2. Possible new approach to treating deadly leukemia in babies
3. New drug shows potential for treatment-resistant leukemia
4. ASH partners with AMEH and National Cancer Institute to improve diagnosis of leukemia in Mexico
5. Tracking down the origin of leukemia relapse
6. New approach to leukemia chemotherapy -- is a cure in sight?
7. UCSF researchers identify promising new treatment for childhood leukemia
8. Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with imatinib
9. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
10. Less Is More With Acute Myeloid Leukemia Drug
11. When leukemia returns, gene that mediates response to key drug often mutated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
Breaking Medicine Technology: